US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Eikon Therapeutics (EIKN): Late-Stage Immuno-Oncology IPO Prices with Strength, Flops on Debut

Eikon Therapeutics (EIKN): Biotech Targeting Advanced Melanoma Sets Terms

Eikon Therapeutics (EIKN): Peeking at the IPO Prospectus of Targeting Advanced Melanoma

IPOs and Secondary Offerings

Equity Capital Markets

Eikon Therapeutics / Equity Capital Markets

<ul>
<li>Eikon Therapeutics (EIKN) is offering 17.6 million shares at $16–$18, targeting a $807–$908 million market capitalization.</li>
<li>The company’s lead asset, EIK1001, is in a global Phase 2/3 melanoma trial, supported by its proprietary single-molecule tracking technology.</li>
<li>Founded by former Merck executives, Eikon is backed by a $30 million Merck investment and strong early demand signals ahead of pricing.</li>
</ul>


Eikon Therapeutics (EIKN) is offering 17.6 million shares at $16–$18, targeting a $807–$908 million market capitalization.
The company’s lead asset, EIK1001, is in a global Phase 2/3 melanoma trial, supported by its proprietary single-molecule tracking technology.
Founded by former Merck executives, Eikon is backed by a $30 million Merck investment and strong early demand signals ahead of pricing.


Eikon Therapeutics (EIKN): メルクの卒業生が後期段階の免疫腫瘍学IPO候補をリード